Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder CancerHomayoun Zargar, Peter C. Black, Yair Lotan et al.|European Urology|2014Cited by 297
Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical CystectomyHomayoun Zargar, Jay B. Shah, Bas W. van Rhijn et al.|The Journal of Urology|2018Cited by 80
The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomyAnna J. Black, Peter C. Black, Homayoun Zargar et al.|Urologic Oncology Seminars and Original Investigations|2019Cited by 44
Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancerDavid D‘Andrea, Shahrokh F. Shariat, Peter C. Black et al.|Urologic Oncology Seminars and Original Investigations|2020Cited by 23
Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinomaDavid D‘Andrea, Shahrokh F. Shariat, Surena F. Matin et al.|British Journal of Urology|2020Cited by 16